Drug discovery and high-throughput screening
3 European H2020 organizations list this as part of their work — 2 as their primary capability.
Most active in this area
- INSTITUT DE RECHERCHES SERVIER
French pharmaceutical research institute contributing drug discovery, screening platforms, and disease models to European oncology and neurodegeneration consortia.
“Core contributor to ESCulab (European Screening Centre), MELLODDY (ML for drug discovery), and IMPRiND (druggable targets for neurodegeneration).”
PrimaryFR9 projects - STEMCELL TECHNOLOGIES UK LTD
Cambridge-based SME providing stem cell reagents and organoid culture platforms for drug discovery, virology, and tissue engineering research.
“OrganoVIR and MAD-CoV 2 use high-throughput approaches; NEUcrest applies genomic tools to identify therapeutic targets.”
SMEUK7 projects - GRUNENTHAL GMBH
German pharmaceutical company specializing in pain therapeutics, contributing drug discovery, clinical expertise, and digital health capabilities to EU pain research consortia.
“NGN-PET developed pain-specific drug discovery platforms, ESCulab provided access to European screening compound libraries, and BonePain trained next-generation pain researchers.”
PrimaryDE7 projects